Imaging of β-oxidation by static pet with 14(R, S)-[18F]-fluoro-6-thiaheptadecanoic acid (FTHA) in patients with advanced coronary heart disease a comparison with 18fdg-pet and 99Tcm-mibi spet

Nuclear Medicine Communications

Volumn 17, Issue 12, 1996, Pages 1057-1064

  Schulz, Gemot ^a   Kaiser, H J ^a   Sabri, O ^a   Banneitz, L ^a   Cremerius, U ^a   Buell, U ^a   Vom Dahl, J ^a   Koch, K C ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

14 FLUORO 6 THIAHEPTADECANOIC ACID F 18; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FATTY ACID METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030448733     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199612000-00010     Document Type: Article

References (35)

1. Tillisch T, Brunken R, Marshall R et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
2. Marwick TH, Maclntrye WJ, Lafont A et al. Metabolic response of hibernating and infarcted myocardium to revascularisation: A follow-up study of regional perfusion, function, and metabolism. Circulation 1992; 85: 1347-1353.
3. vom Dahl J, Eitzman DT, Al-Aouar ZR et al. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. Circulation 1994; 90: 2356-2366
4. Altehoefer C, Kaiser HJ, Doerr R et al Fluorine-18 deox-yglucose PET for assessment of viable myocardium in perfusion defects in 99mTc-MIBI SPECT: A comparative study in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 334-342.
5. vom Dahl J, Altehoefer C, Sheehan FH et al Recovery of regional left ventricular dysfunction following coronary revascularisation: Impact of myocardial viability assessed by nuclear imaging and of vessel patency at follow-up angiography J Am Coll Cardiol (in press).
6. Knuuti MJ, Saraste M, Nuutila P et al. Myocardial viability: Fluorine-18-deoxyglucose positron emisson tomography in prediction of wall motion recovery after revascularisation. Am Heart J 1994; 127: 785-796.
7. Lucignani G, Paolini G, Landoni C et al Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography in patients with chronic coronary artery disease. Eur J Nucl Med 1992; 19: 874-881.
8. Ebert A, Herzog H, Gerhard L et al. Kinetics of 14(R, S)-fluorine-18-fluoro-6-thiaheptadecanoic acid in normal human hearts at rest, during excercise and after dipyridamole injection. J Nucl Med 1994; 35: 51-56.
9. DeGrado TR, Coenen HH, Stoecklin G. 14(R, S)-(18F)-fluoro-6-thia-heptadecanoic acid (FTHA): Evaluation in mouse of a new probe of myocardial utilisation of long chain fatty acids. J Nucl Med 1991; 32: 1888-1896.
10. Freundlieb C, Hoeck A, Vyska K et al Myocardial imaging and metabolic studies with (17-1231) heptadecanoic acid. J Nucl Med 1980; 21: 1043-1050.
11. Stone CK, Rommelfanger S, Holden JE et al. Comparison of fatty acid tracer retention during myocardial ischemia and hypoxia (abstract). J Nucl Med 1996; 37: 94P.
12. Stirner H, Buell U, Kleinhans E. Three-dimensional ROI-based quantification of stress/rest 201 T1 myocardial SPECT: Presentation of method. Nuklearmedizin 1986; 25: 128-133.
13. Altehoefer C, vom Dahl J, Biedermann M et al. Significance of defect severity in technetium-99m-MIBI-SPECT at rest to assess myocardial viability: Comparison with fluorine-18-FDG PET. J Nucl Med 1994; 35: 569-574.
14. Tamaki N, Fujibayashi Y, Magata Y, Yonekura Y, Konishi J. Radionuclide assessment of myocardial fatty acid metabolism by PET and SPECT. J Nucl Cardiol 1995; 2: 256-266.
15. Evans JR, Gunton RW, Baker RG, Beanlands DS, Spears JC. Use of radioionated fatty acid for photoscan of the heart. Circ Res 1965; 16: 1-10.
16. Reske SN. Radiopharmakologische Grundlagen und kli-nische Aussagekraft der Myokardszintigraphie mit 123J-markierten Fettsáuren. Nuklearmedizin 1987; 26: 123-128.
17. Katz AM, Messineo FC. Lipid-membrane interactions and the pathogenesis of ischemic damage in the myocardium. Circ Res 1981; 48: 1-20.
18. Liedke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981; 23: 321-336.
19. Dudczak R, Kletter K, Frischauf H et al. The use of 1231 labelled heptadecanoid acid (HDA) as metabolic tracer. Eur J Nucl Med 1984; 9: 81-85.
20. Sobel BE, Weiss E, Welch M, Siegel B, Ter-Pogossian M. Detection of remote myocardial infarction in patients with positron emission transaxial tomography and intravenous C-ll-palmitate. Circulation 1977; 55: 853-857.
21. Klein M, Goldstein R, Welch M, Sobel B. External assessment of myocardial metabolism with C-ll-palmitate in rabbit hearts. Am J Physiol 1979; 237: H51-58.
22. Tamaki N, Kawamoto M, Takahashi N et al. Assessment of myocardial fatty acid metabolism with positron emission tomography at rest and during dobutamine infusion in patients with coronary artery disease. Am Heart J 1993; 125: 702-710.
23. Fox KA, Abendschein DR, Ambos HD, Sobel BE, Bergman SR. Efflux of metabolized and nonmetabolized fatty acid from canine myocardium: Implications for quantifying myocardial metabolism tomographically. Circ Res 1985; 57: 232-243.
24. Henrich MM, Vester E, von der Lohe E et al. The comparison of 2-18F-2-deoxyglucose and 15-(ortho-123I-phenyl)-pentadecanoic acid uptake in persisting defects on thallium-201 tomography in myocardial infarction. J Nucl Med 1991; 32: 1353-1357.
25. Murray G, Schad N, Ladd W et al. Metabolic cardiac imaging in severe coronary disease: Assessment of vability with iodine-123-iodophenylpentadecanoic acid and multicrystal gamma camera, and correlation with biopsy. J Nucl Med 1992; 33: 1269-1277.
26. Roesler H, Hess T, Weiss M et al. Tomoscintigraphic assessment of myocardial metabolic heterogeneity. J Nucl Med 1983; 24: 285-296.
27. Taki J, Nakajima K, Matsunari I et al. Impairment of regional fatty acid uptake in relation to wall motion and thallium-201 uptake in ischaemic but viable myocardium: Assessment with iodine-123-labelled beta-methyl-branched fatty acid. Eur J Nucl Med 1995; 22: 1385-1392.
28. Reske SN, Nitsch J, von der Lohe E et al. Eingeschrànkte myokardiale Fettsáure-Utilisation bei koronarer Herzerk-rankung nach symptomenlimitierter ergometrischer Belas-tung: Nachweis pathologischer Stoffwechselmuster mit Hilfe von J-123-Phenylpentadekansáure und sequentieller SPECT. Z Kardiol 1989; 78: 262-270.
29. Buell U, Foroutan Y, Hellwig D et al. Vergleich von relativer 18FDG-Aufnahme mit metabolischer Rate (MRGlukose) im Myokard bei KHK, klassifiziert mit 99mTc-MIBI. Nuklearmedizin 1995; 34: 223-228.
30. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of the heart muscle. Ann Rev Physiol 1974; 36: 413-459.
31. Tamaki N, Tadamura E, Kawamoto M et al. Decreased uptake of iodinated branched fatty acid analog indicates metabolic alterations in ischemic myocardium. J Nucl Med 1995; 36: 1974-1980.
32. Gropler RJ, Siegel BA, Lee KJ et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990; 31: 1749-1756.
33. Altehoefer C, vom Dahl J, Buell U. Sepal glucose metabolism in patients with coronary artery disease and left bun-dle-branch block. Coronary Artery Dis 1993; 4: 569-572.
34. Ohtake T, Youkoyama I, Toshiaki W et al. Myocardial glucose metabolism in noninsulin-dependent diabetes melli-tus patients evaluated by FDG-PET. J Nucl Med 1995; 36: 456-463.
35. Perrone-Filardi P, Bacharach SL, Dilsizian V et al. Clinical significance of reduced regional myocardial glucose uptake in regions with normal blood flow in patients with chronic coronary artery disease. J Am Coll Cardiol 1994; 23: 608-616.